Drug Trial Radar · NCT04549597
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
Last checked: Nov 19, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
333
Actual
Start
Nov 20, 2020
Primary completion
Oct 13, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- ArdelyxIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label study to evaluate different methods of initiating tenapanor therapy in CKD patients on dialysis with hyperphosphatemia, when they are either phosphate binder naïve or on phosphate binder therapy. The objective to evaluate the effect of tenapanor alone or in combination with phosphate binders to achieve target serum phosphorus (s-P) levels of ≤5.5 mg/dL when tenapanor is administered as the core therapy (alone or in combination with phosphate binders) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis
- Hyperphosphatemia
Interventions
TenapanorDrug
Use of tenapanor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of Tenapanor to Achieve Target s-P Levels of Less Than or Equal to 5.5 mg/dLTime frame: 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
South Florida Research Institute
Lauderdale Lakes, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.